Startup funding report UK: £481.3m raised across Biotech, Health and SaaS (4–8 May 2026).
It's Friday, 8 May, and this is your UK Startup Funding Report.
This week saw a string of large biotech and healthtech rounds alongside notable raises from SaaS and deep‑tech startups. In total, companies announced around £481.3m of funding across the UK between 4–8 May 2026.
Biotech backs late-stage trials and manufacturing
Late-stage and translational biotech deals dominated this week, with funding directed at registration-enabling clinical trials, microbiome programmes and the manufacturing platforms needed to scale synthetic biology. The pattern underlines that investors remain willing to back companies that can move therapies and industrial biology from the lab toward market.
Notable rounds include CellCentric's oversubscribed growth raise of £162.29 million to advance its oral p300/CBP inhibitor inobrodib into registration-enabling trials for relapsed or refractory multiple myeloma and to support Phase 2 and planned global Phase 3 studies. Cytospire secured £61 million in a Series A led by 4BIO Capital to push pan‑gamma delta T‑cell engagers, including CYT X300, towards first‑in‑human trials and to underwrite IND‑enabling work and GMP manufacturing. EnteroBiotix raised £19 million to move its full‑spectrum microbiome therapeutic EBX‑102‑02 into a 300‑patient Phase 2b trial for IBS‑C, and NunaBio attracted £6.5 million to scale a cell‑free synthetic DNA platform aimed at increasing UK manufacturing capacity for complex sequences.
Taken together, the rounds show capital flowing both to late‑stage clinical programmes and the infrastructure that supports them. London and Cambridge remain active hubs, but deals from Glasgow to Newcastle point to national investor interest. The question now is whether more capital will follow to support manufacturing scale‑up alongside clinical pipelines.
This week's Health & Biotech deals:
CellCentric closed an oversubscribed growth round of £162.29m to advance its oral p300/CBP inhibitor, inobrodib, into registration‑enabling trials for relapsed or refractory multiple myeloma. The funding will support Phase 2 and planned global Phase 3 studies and broaden combination programmes with existing therapies.
Cytospire raised £61m in a Series A led by 4BIO Capital to push its pan‑gamma delta T cell engagers, including CYT X300, towards first‑in‑human trials in EGFR‑positive solid tumours. The funds will underwrite IND‑enabling studies, GMP manufacturing and early clinical development.
EnteroBiotix raised £19m to move its full‑spectrum microbiome therapeutic EBX‑102‑02 into a 300‑patient Phase 2b trial for IBS‑C. The funding will support the RISE study, manufacturing and broader GI pipeline development.
NunaBio raised £6.5m to scale an enzymatic, cell‑free synthetic DNA platform aimed at increasing UK manufacturing capacity for complex sequences. The investment will support production scale‑up and commercial partnerships for synthetic DNA applications.
Agent-driven automation moves into the enterprise
Investor interest this week favoured agent‑based AI and automation that produce verifiable, auditable outputs for enterprise workflows, hiring and trust and safety. The emphasis is on deployable agents that replace manual processes—CV screening, content moderation and user acquisition operations—with measurable, closed‑loop automation.
Ethos raised £16.7 million to develop an AI agent that assesses expertise through short voice chats and work‑sample analysis as an alternative to CVs, aiming to broaden product development and scale matching for specialist and gig roles. CodeWords secured £6.6 million to scale Cody, an agent that designs and runs automated workflows for non‑technical teams, while Kohort raised £5.15 million to build UA agents that automate campaign optimisation using predictive lifetime‑value models for mobile game studios. Checkstep’s £3 million seed will support an AI‑driven trust and safety platform for content moderation and regulatory compliance.
These rounds suggest investors are prioritising commercialisation over pure research, with London as a concentration point. The coming months will show whether customers accept these agents in live workflows and whether the promised ROI materialises at scale.
This week's AI & Automation (agents, enterprise software, trust & safety) deals:
Ethos raised £16.7m to develop its AI agent that assesses expertise via short voice chats and work‑sample analysis as an alternative to CVs. The funding will broaden product development and help the company scale matching for specialist and gig roles.
CodeWords raised £6.6m to scale Cody, its AI agent that designs and runs automated workflows for non‑technical teams. The funds will broaden engineering capacity and commercialisation to increase adoption across enterprises and agencies.
Kohort raised £5.15m to develop UA agents that automate campaign optimisation using predictive lifetime‑value models. The funding will accelerate product work that aims to improve user acquisition efficiency for mobile game studios.
Checkstep raised £3m in seed funding to develop its AI‑driven Trust and Safety platform for content moderation and regulatory compliance. The company will use the money to add features and expand sales as regulation tightens across the EU and US.
Infrastructure bridges TradFi and crypto
Growth capital is flowing to infrastructure plays that link traditional finance and crypto, and to firms that supply decision‑grade private‑company data. Clearer regulation and institutional demand are helping these platforms scale as they target fintechs, exchanges and data‑driven institutional users.
OpenTrade raised £12.5 million to expand regulated stablecoin yield infrastructure and curated vault services for fintechs, exchanges and neobanks, using the funds to scale distribution and grow investment and engineering teams. Beauhurst secured £7 million to widen coverage of private‑company data across Europe, scale localised data operations and enter new markets. Both deals reflect appetite for infrastructure that integrates into institutional workflows.
The cluster points to a pragmatic investor shift towards revenue‑bearing infrastructure rather than speculative token plays, with London continuing to anchor regulated product development. The next test will be how quickly these platforms convert institutional interest into recurring revenue.
This week's Fintech, Crypto & Data Infrastructure deals:
OpenTrade raised £12.5m to expand its regulated stablecoin yield infrastructure and curated vault services for fintechs, exchanges and neobanks. The capital will be used to scale permissioned and permissionless distribution and grow investment and engineering teams.
Beauhurst raised £7m to expand decision‑grade private company data coverage across Europe and support its commercial growth. The capital will be used to scale localised data operations and enter new markets.
Hard‑tech funding targets production‑ready hardware
Investors are underwriting hard engineering risk this week, backing materials‑led and hardware startups that aim to make advanced technologies production ready for AI, data‑centre and decarbonisation use cases. The current funding cycle favours companies that pair novel hardware with clear manufacturing and deployment plans.
Quantum Motion raised £120 million in a Series C to scale silicon‑transistor quantum processors for data‑centre deployment and accelerate engineering and manufacturing to make quantum hardware rack‑compatible. Nyobolt secured £44 million to scale high‑power, fast‑charging battery systems for autonomous machines and edge AI infrastructure and to fund product development and international expansion. Barocal closed £7.39 million to commercialise solid‑state, refrigerant‑free heating and cooling technology for data centres and commercial refrigeration, while WaiV Robotics raised about £5.53 million to launch a gyro‑stabilised platform that recovers VTOL drones from small, moving vessels.
These rounds span Cambridge and London and use cases from data centres to maritime operations. The companies that clear pilot demonstrations and secure anchor customers first will reveal who can scale industrial hardware profitably.
This week's Deeptech, Hardware & Greentech deals:
Quantum Motion raised £120m in a Series C to scale its silicon transistor quantum processors designed for data‑centre deployment. The cash will accelerate engineering and manufacturing work aimed at making quantum hardware compatible with standard data centre racks.
Nyobolt secured £44m to scale its high‑power, fast‑charging battery systems for autonomous machines and edge AI infrastructure. The investment will fund product development and international expansion as the company pursues deployments in robotics and off‑grid AI data centres.
Barocal closed £7.39m to commercialise its solid‑state, refrigerant‑free heating and cooling technology for data centres and commercial refrigeration. The funds will support system development, engineering hires and moves toward pilot demonstrations.
WaiV Robotics raised approximately £5.53m to launch a gyro‑stabilised landing and takeoff platform that recovers VTOL drones from small, moving vessels. The product aims to remove a key operational barrier for maritime drone operations and support offshore use cases.
🎧 That's this week's Startupmag Weekly Briefing.
See you next Friday for another look at the UK startup scene.